Literature DB >> 9783780

Characteristics and clinical outcome of proximal-third gastric cancer.

T Sakaguchi1, A Watanabe, H Sawada, Y Yamada, M Tatsumi, H Fujimoto, K Emoto, H Nakano.   

Abstract

BACKGROUND: It is generally accepted that the prognosis of patients with proximal gastric cancer (PGC) is worse than that of patients with more distal gastric cancer. STUDY
DESIGN: The aim of this study was to compare the clinical features and outcomes of PGC with those of middle- and distal-third gastric cancers. A total of 646 primary gastric cancers was analyzed as a retrospective study.
RESULTS: Proximal gastric cancer occurred in 21.8% of the 646 cancers analyzed, and approximately 21% of PGCs had esophageal invasion. The 5-year survival rate for patients with PGC was significantly lower than that of patients with more distal tumors. When the PGC group was divided into patients with esophageal invasion and without esophageal invasion, patients with esophageal invasion had significantly worse outcomes. When corrected for depth of invasion, lesions with esophageal invasion had significantly worse outcomes than those of other sites in T2 curative cancers. Proximal gastric cancer with esophageal invasion was characterized by a larger tumor, deeper penetration, and a higher incidence of lymph node metastasis compared with tumors in other sites, and in multivariate analysis of all curative cases, these variables were independent prognostic factors for survival. The frequency of positive proximal margins of PGC was higher than those of other sites.
CONCLUSIONS: The relatively poor prognosis associated with PGC is mainly from advanced tumor stages of esophageal invasion. Early detection is the most important strategy to improve the survival of patients with PGC. In addition, aggressive lymph node dissection and chemotherapy for esophageal invasion should be considered even if the tumor invasion is moderate (T2 tumor), and a tumor-free margin is important.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9783780     DOI: 10.1016/s1072-7515(98)00191-4

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  23 in total

1.  Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

Authors:  Manish A Shah; Minaxi Jhawer; David H Ilson; Robert A Lefkowitz; Edric Robinson; Marinela Capanu; David P Kelsen
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

Review 2.  [R1 resection of esophageal carcinoma].

Authors:  I Gockel; C Wittekind
Journal:  Chirurg       Date:  2017-09       Impact factor: 0.955

Review 3.  Clinical impact of tumour biology in the management of gastroesophageal cancer.

Authors:  Florian Lordick; Yelena Y Janjigian
Journal:  Nat Rev Clin Oncol       Date:  2016-03-01       Impact factor: 66.675

4.  Turning left or right? A comparative analysis in adenocarcinomas of the esophagogastric junction according to the seventh AJCC TNM classification for cancers of the esophagus and stomach: experience in a Chinese single institution.

Authors:  Enhao Zhao; Tianlong Ling; Jia Xu; Gang Zhao; Hui Cao; Simone Giacopuzzi; Maria Bencivenga; Giovanni de Manzoni
Journal:  Int J Clin Exp Med       Date:  2015-07-15

5.  Gastric cancer: Where is the place for the surgeon, the oncologist and the endoscopist today?

Authors:  Markus Menges
Journal:  World J Gastrointest Oncol       Date:  2011-01-15

6.  Diversity of clinical implication of B-cell translocation gene 1 expression by histopathologic and anatomic subtypes of gastric cancer.

Authors:  Mitsuro Kanda; Hisaharu Oya; Shuji Nomoto; Hideki Takami; Dai Shimizu; Ryoji Hashimoto; Satoshi Sueoka; Daisuke Kobayashi; Chie Tanaka; Suguru Yamada; Tsutomu Fujii; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Michitaka Fujiwara; Yasuhiro Kodera
Journal:  Dig Dis Sci       Date:  2014-12-09       Impact factor: 3.199

7.  Safety and Feasibility of Carboplatin and Paclitaxel followed by Fluoropyrimidine Analogs and Radiation as Adjuvant Therapy for Gastric Cancer.

Authors:  Mohammad Mobayed; Lance K Heilbrun; Anthony F Shields; Tara Washington; Raghu Venkatramanamoorthy; Philip A Philip; Bassel F El-Rayes
Journal:  Case Rep Oncol       Date:  2009-11-21

8.  Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.

Authors:  Andrew P Barbour; Nabil P Rizk; Mithat Gonen; Laura Tang; Manjit S Bains; Valerie W Rusch; Daniel G Coit; Murray F Brennan
Journal:  Ann Surg       Date:  2007-07       Impact factor: 12.969

Review 9.  Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction.

Authors:  Markus Menges; Thomas Hoehler
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-04       Impact factor: 4.553

10.  Prognosis of upper-third gastric carcinoma patients with invasion of the lower esophagus.

Authors:  Seong Yeob Ryu; Jae Kyoon Joo; Jae Hyuk Lee; Dong Yi Kim
Journal:  Langenbecks Arch Surg       Date:  2008-05-16       Impact factor: 3.445

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.